# Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

> **NCT05544214** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 32 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** CKD-371

## Key facts

- **NCT ID:** NCT05544214
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-21
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-17
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544214, "Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05544214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*